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EXECUTIVE SUMMARY 
Abstract: The purpose of this study was to determine if intraoperative use of tranexamic acid 
(TXA) was associated with estimated blood loss in patients who underwent elective craniofacial 
surgery. 
 
Introduction: Intraoperative blood loss has been shown to significantly contribute to 
postoperative morbidity and mortality in patients undergoing surgical procedures. It is the 
responsibility of the anesthesia clinician to accurately assess and actively replace ongoing blood 
loss, as well as employ strategies to curtail perioperative hemorrhage. While numerous methods 
exist to minimize surgical blood loss, such as mild hypothermia and controlled hypotensive 
techniques, these interventions can prove hazardous in pediatric patients and those with multi-
morbidities. Additionally, allogenic blood transfusions possess unique risks in the form of 
transmissible disease and transfusion complications. It is imperative that the safest, scientifically-
proven, most cost-effective, methods be adopted into clinical practice. This will help to ensure 
optimization of surgical outcomes, reduction in health care costs, and promotion of patients 
along the wellness continuum. Therefore, antifibrinolytic therapy is being utilized to aid in the 
reduction of perioperative blood loss. The more recent use of perioperative Tranexamic Acid to 
decrease surgical blood loss has assisted in achievement of these goals. The findings of this study 
could be directly applied to patients undergoing elective craniofacial surgery at CAMC and other 
facilities world-wide. The Certified Registered Nurse Anesthetist (CRNA) will be able to safely 
implement the results of this evidenced based research into daily practice.  
 
Methodology: A retrospective, quantitative, cohort study design was utilized for this research. A 
systematic chart review was completed of patients age three months – 35 years old, American 
Society of Anesthesiologist (ASA) physical classification I-III, who underwent elective 
craniofacial surgery between June 1, 2008 and June 1, 2018. A total of 108 patients were 
included in the study and were classified into two groups: Group 1 was comprised of 54 patients 
who did not receive intraoperative TXA; Group 2 consisted of 54 patients who did receive 
intraoperative TXA.  Primary independent variables were administration of TXA or no 
administration of TXA. Additional independent variables included age, gender, body mass index 
(BMI), and ASA physical status. The dependent variables were estimated blood loss and the 
need for intraoperative blood transfusion. The hypotheses of this study were that intraoperative 
administration of TXA in patients who underwent elective craniofacial surgery would be 
associated with decreased estimated surgical blood loss and a decreased need for blood 
transfusion throughout the operative period versus patients who did not receive intraoperative 
TXA. 
 
Results: The patient population for this study consisted of 108 patients classified into Group 1 
(54 patients who did not receive intraoperative TXA) and Group 2 (54 patients who did receive 
TXA intraoperatively).  Mean age of patients was 9.81 ± 9.06 years. Average BMI was 21.73 ± 
6.28 kg/m2. Average estimated blood loss, expressed as percentage of EBV, was 13.80 ± 
14.71%. No statistical differences were found between the two groups in regard to age and BMI 
(p = 0.962 and 0.410, respectively). Additionally, there was no statistical significance between 
Group 1 and 2 in gender and ASA classification (p =0.700 and 0.701, respectively). Step-wise 
regression showed no statistically significant relationship existed between TXA administration, 
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transfusion requirements, and estimated blood loss. However, step-wise regression results 
indicated a significant association between age and estimated blood loss. Logistic regression 
analysis revealed a significant association between age and blood transfusion (p = .000). Gender, 
ASA classification, and TXA administration were not significantly associated with intraoperative 
blood transfusion. As age increased patients were less likely to receive intraoperative blood 
transfusion (p = .021).  
 
Discussion: The results of this study did not support the hypotheses that intraoperative 
administration of TXA in patients who underwent elective craniofacial surgery would be 
associated with decreased estimated surgical blood loss and a decreased need for blood 
transfusion throughout the operative period versus patients who did not receive intraoperative 
TXA. Since intraoperative administration of TXA was not significantly associated with decrease 
in blood loss or need for intraoperative blood transfusion, the hypotheses were rejected. 
 
Conclusion: The intraoperative administration of TXA was not associated with decreased 
estimated surgical blood loss or decreased need for intraoperative blood transfusion in patients 
who underwent elective craniofacial surgery. The results of this retrospective, cohort study 
concluded that increasing patient age was associated with both decreased likelihood for blood 
transfusion as well as decreased estimated blood loss. 
 
Key Words: antifibrinolytic drugs, blood loss, craniofacial surgery, tranexamic acid, transfusion 
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INTRODUCTION 
Background and Significance 
 According to the American Society of Plastic Surgeons (ASPS), almost 220,000 
craniofacial and maxillofacial surgeries were performed in the United States (U.S.) in 2016 
(American Society of Plastic American Society of Plastic Surgeons, 2017). These procedures 
include craniosynostosis correction, cleft lip and palate repair, and orthognathic surgery. 
Anomalies of the craniofacial region can be congenital or acquired and involve a wide range of 
defects (Davis, Cladis, & Motoyama, 2011). 
Surgical correction for craniofacial abnormalities has been linked to significant 
perioperative blood loss due to the vascularity of the surgical field (Choi, Irwin, & Samman, 
2009). Intraoperative bleeding not only poses a threat to homeostasis but has a direct effect on 
surgeon efficacy (Christabel et al., 2014).  Additionally, risks of allogenic blood transfusion can 
include transmission of infectious disease and transfusion associated complications (Sankar, 
Krishnan, Veerabahu, & Vikraman, 2012). Prevention and treatment of excessive bleeding in the 
operating room (OR) is paramount for a positive clinical outcome. While the necessity of blood 
transfusion is sometimes unavoidable, it is prudent to employ strategies to curtail the use of these 
scarce resources (Faverani et al., 2014). 
 Various methods to decrease intraoperative bleeding have been utilized including 
hypothermia, hypocapnia, mild hypotensive technique, autologous transfusion, and 
normovolemic hemodilution. (Meara et al., 2005). However, due to the risks associated with 
some of these methods in vulnerable populations, it would be judicious to explore alternative 
techniques to decrease intraoperative bleeding, such as antifibrinolytic therapy (Song et al., 
2013). Antifibrinolytic medications, such as tranexamic acid (TXA), work by competitive 
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inhibition of plasmin to fibrin binding sites as well as inhibition of plasminogen to plasmin 
conversion (Dunn & Goa, 1999).  
Literature Review 
TXA is a synthetic lysine analogue with initial studies dating back to 1962 (Slaughter & 
Greenberg, 1997). It has 6 to 10 times the binding capacity of other synthetic antifibrinolytic 
drugs and has been shown to be more cost effective than aprotinin. TXA has been used to reduce 
operative bleeding in a variety of settings, such as open-heart surgery, orthopedics, menorrhagia, 
gastrointestinal bleeding, liver transplantation, transurethral resection of the prostate (TURP), 
and craniofacial surgery (Dunn & Goa, 1999). Reported elimination half-life of TXA is 
approximately 1-1.5 hours and studies support continuous intravenous administration of 
antifibrinolytic therapy during the perioperative stage to ensure therapeutic blood concentrations 
are achieved (Slaughter & Greenberg, 1997). 
A 1974 study completed on healthy volunteers revealed that TXA distribution followed 
an open, two-compartment model with glomerular filtration being the primary route of 
elimination after a single intravenous dose (Eriksson, Kjellman, Pilbrant, & Schannog, 1974). 
Further studies indicated over 95% of each dose is eliminated as chemically unaltered drug in the 
urine. Therefore, dosage adjustment should be considered in patients with documented renal 
insufficiency. Recommendations for general fibrinolysis include a single intravenous dose of 
10mg/kg or 1g of TXA (Dunn & Goa, 1999). Agreement is lacking in regard to timing of 
administration. However, most literature supports preoperative administration of TXA, with the 
decision for continuous infusion at the discretion of the clinician (Choi et al., 2009). 
Concerns regarding the potential of antifibrinolytic therapy to promote thromboembolic 
events have been cited by numerous studies. Pharmacologically, TXA serves to stabilize formed 
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blood clots by slowing fibrinolysis and has not been reported to exhibit prothrombotic effects. 
Therefore, it does not appear that TXA contributes to the risk of perioperative thrombosis 
(Slaughter & Greenberg, 1997). 
 A secondary examination was completed of 35,478 pediatric patients who received TXA 
during a single hospital encounter between 2009 and 2013. Data were collected using the 
Pediatric Health Information System (PHIS) which contains information from 36 U.S. children’s 
hospitals affiliated with the Children’s Hospital Association. Of those included in the study, 
1275 patients received TXA for craniofacial surgery. Results also denoted a broad range of 
indications for tranexamic use in the pediatric population (Nishijima et al., 2016). 
 A randomized, double-blind trial was conducted on 66 patients who underwent 
palatoplasties from January through December 2014 at the Facial Defects Awareness Center of 
the Professor Fernando Figueira Internal Medicine Institute (CADEFI) in Brazil. Patients in the 
study group received a 10mg/kg TXA bolus followed by a 1mg/kg continuous infusion for the 
duration of surgery. Control group patients received a placebo. In this clinical trial, intraoperative 
blood loss was calculated as a percentage of the patient’s estimated total circulating blood 
volume. Results indicated an 11.9% diminution in intraoperative bleeding in the study group 
compared to the control group (Arantes, Pereira, de Melo, Alonso, & Duarte, 2017).  
 In 2009, Choi, Irwin, and Samman studied 73 patients scheduled for orthognathic 
surgery. The purpose of the clinical trial was to determine if a correlation existed between single 
dose preoperative TXA and intraoperative blood loss. Anesthetic plan for all patients involved a 
mild controlled hypotensive technique. The intervention group received 20mg/kg TXA prior to 
surgery start and the control group received 0.9% normal saline. Average blood loss total in the 
treatment group was 878.6 ml compared to 1257.2 ml in the control group – a difference of 422 
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ml. These results were calculated to be statistically significant and indicated the usefulness of 
TXA in intraoperative blood loss reduction (Choi et al., 2009). 
 A similar prospective, randomized, triple-blinded study was performed with isolated Le 
Fort I osteotomies in Chennai, India in 2013. Hypotensive anesthesia was also utilized in this 
trial. A sample size of 49 patients were included with age range 18-34 years. Thirty minutes prior 
to induction, Group 1 (control) received a placebo of saline and Group 2 (intervention) received 
10mg/kg TXA. Operating time and total blood loss was significantly reduced in Group 2 
compared to Group 1. Total blood loss in the intervention group revealed a 45% reduction when 
compared to the control group. Additionally, lab values revealed a significant variance in 
preoperative and postoperative hemoglobin and packed cell volume. These findings also suggest 
single intravenous preoperative administration of TXA may diminish the need for postoperative 
blood transfusion (Christabel et al., 2014). 
 Multiple other studies have supported the use of antifibrinolytic therapy for orthognathic 
surgery. Mohammadi and Hasheminasab (2012) demonstrated a positive correlation between 
preoperative administration of TXA and blood loss reduction during bimaxillary osteotomy 
surgery. A 2012 study analyzed the difference in surgical field visibility, case duration, and total 
blood loss among patients undergoing orthognathic surgery who received TXA in conjunction 
with hypotensive anesthesia versus hypotensive technique alone. Statistical significance existed 
when comparing estimated blood loss and quality of the surgical field between the two groups 
(Sankar et al., 2012). Further, meta-analysis completed by Song et al. (2013) confirmed the 
efficacy of TXA in reducing intraoperative blood loss during orthognathic surgery. 
The use of TXA has also been shown to be effective in reducing blood loss in patients 
who underwent craniosynostosis correction. A 2010 study completed in France showed a 
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statistically significant difference in volume and number of transfused packed red blood cells 
among 40 children who received a 15mg/kg bolus of TXA followed by a 10mg/kg/hr infusion 
versus saline placebo. Patients in this study also received erythropoietin pre-operatively per 
institution protocol (Dadure et al., 2011). Similarly, a 2015 single-center study in Germany 
reported a significant decrease in blood loss and packed red blood cell transfusion after TXA 
administration in 40 patients who underwent fronto-orbital advancement. In this study, the 
intervention group received a 10mg/kg bolus followed by 5mg/kg/hr continuous infusion while 
the control group received no TXA (Engel et al., 2015). 
A unique, randomized, double-blind study of 60 patients investigated the ability of TXA 
to control common side effects of rhinoplasty (intraoperative bleeding, periorbital ecchymosis, 
and eyelid edema) that were commonly managed with corticosteroids. 10mg/kg of TXA or 
placebo was administered intravenously immediately prior to surgery start. All patients received 
dexamethasone 8mg every 8 hours postoperatively. Mean intraoperative bleeding (calculated by 
hematocrit and estimated blood loss), eyelid edema, and periorbital ecchymosis was appreciably 
reduced in the intervention group in contrast to the control group (Ghavimi, Taheri Talesh, 
Ghoreishizadeh, Chavoshzadeh, & Zarandi, 2017). 
 Benefits to use of antifibrinolytic therapy reach further than direct patient outcomes. The 
unit dose cost of antifibrinolytic drugs compared to one unit of packed red blood cells can be 
substantial. Therefore, even a one-unit reduction in transfusion requirements per patient is 
advantageous.  This aggregate expense reduction may assist with unburdening of the health care 
system, especially for those who do not possess a third-party plan (Sepah et al., 2011). 
In 2015, the National Clinical Guideline Centre released evidence-based guidelines and 
recommendations regarding blood transfusion including a cost-effective analysis of cell salvage 
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and tranexamic acid use. An economic evidence profile of tranexamic acid showed an 
incremental cost reduction of £54 (approximately $75.84) when perioperative intravenous 
tranexamic acid was used instead of placebo (National Clinical Guideline Centre, 2015). A cost-
benefit analysis, in conjunction with a Process Improvement Project, that was completed by 
Demos et al. (2017) showed individual patient savings of approximately $128, per encounter, 
with hospital-wide standardization of preoperative TXA administration. Additionally, $55,884 
was reported in annual institution savings following project implementation (Demos et al., 
2017).  
Statement of the Problem 
While an array of techniques have been used to decrease intraoperative bleeding in the 
OR, it is imperative that the safest, scientifically-proven, most cost-effective, methods be 
adopted into clinical practice. This will help to ensure optimization of surgical outcomes, 
reduction in health care costs, and promotion of patients along the wellness continuum.  The 
more recent use of perioperative TXA to decrease surgical blood loss has assisted in achievement 
of these goals. The findings of this study could be directly applied to patients undergoing elective 
craniofacial surgery at CAMC and other facilities world-wide. The Certified Registered Nurse 
Anesthetist (CRNA) will be able to safely implement the results of this evidenced based research 
into daily practice.  
Research Objectives 
The goal of this research was to determine if the intravenous administration of TXA was 
associated with less total estimated blood loss in patients who underwent craniofacial surgery. 
The purpose of this study was to determine if intraoperative use of tranexamic acid (TXA) was 
associated with estimated blood loss in patients who underwent elective craniofacial surgery. 
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METHODOLOGY 
Hypothesis 
The hypotheses for this study were: 
1. Intraoperative administration of TXA in patients who underwent elective craniofacial 
surgery will be associated with decreased estimated surgical blood loss versus patients 
who did not receive intraoperative TXA. 
2. Intraoperative administration of TXA in patients who underwent elective craniofacial 
surgery will be associated with a decreased need for intraoperative blood transfusion 
versus patients who did not receive intraoperative TXA. 
Research Design 
 The study design was a retrospective, quantitative, cohort study conducted at Charleston 
Area Medical Center (CAMC). This study design was employed due to cost effectiveness, ability 
to compare multiple variables within the information snapshot, and timeliness of data collection. 
Electronic medical records (EMR) of patients meeting inclusion criteria were reviewed, which 
allowed for comparison of clinical characteristics and patient demographics. 
Sample 
 A chart review was conducted on patients age 3 months-35 years with ASA classification 
of I-III who underwent elective craniofacial surgery between June 1, 2008 and June 1, 2018 at 
CAMC. One hundred and eight patients who met inclusion criteria were separated into two 
groups: Group 1 was comprised of 54 patients who did not receive intraoperative TXA; Group 2 
consisted of 54 patients who received any dose of intraoperative TXA.  Patients eligible for 
inclusion were identified utilizing The International Classification of Diseases, 9th revision, 
Clinical Modification (ICD-9-CM) codes 01.25 (craniectomy), 01.24 (craniotomy), 01.23 
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(craniectomy, reopening of site), 02.01 (craniectomy, linear/strip), 02.06 (cranioplasty), 73.8 
(craniectomy, fetal), 76.69 (osteotomy, facial bone), 76.66 (osteoplasty, maxilla, total), 76.65 
(osteoplasty, maxilla, segmental), 76.64 (osteoplasty, mandible) 76.63 (osteoplasty, mandible 
body), 76.62 (osteoplasty, ramus, open) 76.61 (osteoplasty, ramus, closed), 76.91 (bone graft to 
facial bone), 76.92 (insertion of synthetic implant in facial bone) and applicable International 
Classification of Diseases, 10th revision, Clinical Modification (ICD-10-PCS) codes (Appendix 
A). 
Inclusion Criteria 
1. Male or female patients age 3 months-35 years old 
2. American Society of Anesthesiologists (ASA) physical classification I-III 
3. Patients who underwent craniofacial surgery and did or did not receive intravenous TXA 
Exclusion Criteria 
1. Patients less than 3 months or greater than 35 years old 
2. Patients with bleeding disorders, clotting disorders, or hemostasis abnormalities 
3. Patients taking TXA at time of craniofacial surgery 
4. Patients who received preoperative blood transfusions 
5. ASA physical classification greater than III 
Procedure 
A retrospective chart review was conducted from electronic medical records on patients 
who underwent elective craniofacial surgery at CAMC from June 1, 2008 through June 1, 2018. 
Pertinent data were collected utilizing patients’ perioperative anesthesia and surgery records. 
Collected data included age, gender, BMI, ASA classification, TXA administration, estimated 
blood loss, and administration of intraoperative blood transfusion. Age was measured in years. 
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Gender classification was male or female. BMI (kg/m2) was calculated using patient height and 
weight obtained from the anesthesia record. A classification system using yes and no was 
employed to indicate if patients received intraoperative TXA. Yes indicated the patient received 
intraoperative TXA and no indicated the patient did not receive TXA. The yes and no system 
was also used to record intraoperative blood transfusion. Yes indicated the patient received 
intraoperative blood transfusion of packed red blood cells and no indicated the patient did not 
receive intraoperative blood transfusion of packed red blood cells. Estimated blood loss (EBL) in 
milliliters was converted into a percentage of blood volume loss (PBVL) by dividing EBL by the 
patient’s estimated total blood volume (EBV). EBV was calculated using the following: 
 
Age EBV 
Neonate 
(1-28 days) 100 ml/kg 
Infants 
(1-11 months) 80 ml/kg 
Child 
1-12 years 75 ml/kg 
Adult 
>12 years 70 ml/kg 
Source: Miller & Pardo, 2011  
The ASA physical status classification is a system developed by the American Society of 
Anesthesiologists to determine the general health of the patient prior to surgery (American 
Society of Anesthesiologists, 2014). The classifications are: 
I. A normal healthy patient. 
II. A patient with mild systemic disease. 
III. A patient with severe systemic disease. 
IV. A patient with severe systemic disease that is a constant threat to life. 
V. A moribund patient who is not expected to survive without the operation. 
VI. A declared brain-dead patient whose organs are being removed for donor purposes. 
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Data Collection and Instrumentation 
Microsoft Excel was utilized by the researcher to systematically organize collected data. 
Each patient was assigned a number in the order the data will be collected. The assigned number 
in no way linked the patient to the data collected. Each patient’s EMR was accessed to obtain 
specific data from the perioperative anesthesia and surgery records. Information gathered from 
these records assisted with delineation of patients into one of two groups: 1. Received 
intraoperative TXA, 2. Did not receive intraoperative TXA. SPSS software was utilized to 
determine the statistical relevance of collected data.  
Statistical Design and Analysis 
 The purpose of this study was to determine if intraoperative administration of TXA was 
associated with decreased blood loss in patients who underwent elective craniofacial surgery. 
Step-wise regression was used to determine if a relationship existed between TXA therapy, 
PBVL, and transfusion administration. Age, BMI, gender, and ASA classification were also 
included in the regression analyses. A t-test was performed to determine if the two groups shared 
similarities in age and BMI. A Chi-squared test was used to determine if the two groups were 
similar in gender and ASA classification. A p-value <0.5 was considered statistically significant. 
Ethical Considerations 
 The study was approved by the CAMC and West Virginia University-Charleston 
Division Institutional Review Board on June 29, 2018. 
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RESULTS 
Presentation, Analysis, and Interpretation of Data  
Table 1. Patient Demographics 
 
Variable No TXA Group 
(Group 1) 
TXA Group 
(Group 2) 
P-Value (2-tailed) 
Mean Age (years) 9.77 9.86 0.962 
Gender (n/%) 
Male 
Female 
 
27 (50%) 
27 (50%) 
 
29 (54%) 
25 (46%) 
0.700 
Mean BMI (kg/m2) 22.23 21.23 0.410 
ASA (n/%) 
I 
II 
III 
 
17 (32%) 
33 (61%) 
4 (7%) 
 
18 (33%) 
34 (63%) 
2 (4%) 
0.701 
Mean PVBL 12% 15% .273 
Received 
Intraoperative Blood 
Transfusion 
16 (30%) 20 (37%) - 
 
*p < 0.05, statistically significant 
The patient population for this study consisted of 108 males and females between the 
ages of three months to 35 years who underwent elective craniofacial surgery from June 1, 2008 
through June 1, 2018 at CAMC. Group 1 was comprised of 54 patients who did not receive 
intraoperative TXA. Group 2 was comprised of 54 patients who did receive TXA 
intraoperatively.  Mean age of patients was 9.81 ± 9.06 years. Average BMI was 21.73 ± 6.28 
kg/m2. PVBL was 13.80 ± 14.71%. 
A t-test determined no statistical difference between the two groups in regard to age and 
BMI (p = 0.962 and 0.410, respectively). Additionally, a Chi-squared test confirmed there was 
no statistical difference between Group 1 and 2 in gender and ASA classification (p =0.700 and 
0.701, respectively). Demographic results are represented in Table 1.  
 
 
18 
 
Table 2. Linear Regression Analysis For Factors Affecting Estimated Blood Loss 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
t p-value R 
square 
B Std. Error Beta 
(constant) 22.11 1.793 - 12.330 .000 - 
Age -.847 .135 -.522 -6.293 .000* .272 
*p < 0.05, statistically significant  
Step-wise linear regression was used to determine if a relationship existed between TXA 
administration, transfusion administration, PVBL, and age. The analysis revealed a significant 
association between age and estimated blood loss with a coefficient of -.847. This showed that 
for every increase in age by one year, PVBL decreased by .847. Linear regression analysis for 
factors affecting estimated blood loss are represented in Table 2. 
Table 3.  Logistic Regression Analysis Results For Factors Affecting Intraoperative Blood  
   Transfusion 
 
Variable Score df p-value  
Age 53.498 1 .000* 
Gender 3.134 1 .077 
TXA Administration .667 1 .414 
ASA I .528 1 .467 
ASA II .079 1 .799 
*p < 0.05, statistically significant 
 
Logistic regression analysis was used to determine if age, gender, TXA administration, 
ASA 1, and ASA 2 were associated with intraoperative blood transfusion administration and 
revealed a significant association between age and blood transfusion only (p = .000). Gender, 
ASA classification, and TXA administration were not significantly associated with intraoperative 
blood transfusion. Logistic regression analysis results for factors affecting intraoperative blood 
transfusion are represented in Table 3.  
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Table 4. Logistic Regression Step 1 
 
 B S.E. Wald df Sig. Exp(B) 
Age -.572 .248 5.339 1 .021* .564 
Constant 1.460 .424 11.851 1 .001 4.305 
*p < 0.05, statistically significant 
 
Step 1 in the Logistic regression (Table 4) showed that as age increased patients were less 
likely to receive intraoperative blood transfusion (p = .021).  
DISCUSSION 
Discussion of Study Results 
 The results of this retrospective, cohort study indicated that there was no statistically 
significant association between the intraoperative administration of TXA and PVBL. 
Additionally, there was no correlation between intraoperative administration of TXA and the 
need for intraoperative blood transfusion. Groups 1 and 2 were not statistically different in age, 
gender, BMI, or ASA Classification. Mean estimated blood loss was similar between the two 
groups. The findings of this study were not consistent with literature reviewed.  
Step-wise linear regression revealed a statistically significant association between age 
and estimated blood loss. As patient age increased by one year, EBVL decreased by a factor of 
.847. Logistic regression determined a significant association existed between age and blood 
transfusion. As patient age increased, the likelihood for blood transfusion decreased.  
While craniofacial surgeries include a wide variety of procedures, this study focused 
primarily on patients who underwent craniosynostosis correction and elective orthognathic 
surgeries. It should be noted that majority of patients included in this study who were less than 
one year of age (n = 39) underwent craniosynostosis correction. This type of corrective surgery is 
associated with significant blood loss requiring blood transfusion  (Engel et al., 2015). This may 
help explain the regression results that indicated increased age was associated with decreased 
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blood loss and likelihood for intraoperative blood transfusion. Conversely, no patients over the 
age of three (n=56) received intraoperative blood transfusions. Majority of these patients 
underwent elective orthognathic surgery. In this study, no patients who underwent orthognathic 
surgery received intraoperative blood transfusions. Additionally, craniosynostosis correction was 
the only procedure in which intraoperative hemoglobin and hematocrit levels were monitored 
through blood specimen collection. Trending of these laboratory values may have contributed to 
the decision to administer packed red blood cells, although cases existed when blood was 
administered prior to the obtainment of these values.  
Although there were only five different lead/primary surgeons included in this study, 
additional required neurological surgeon assistance during craniosynostosis correction may have 
affected overall procedural blood loss due to surgical technique. Furthermore, variation in 
anesthetic techniques were noted. Inhalation agents utilized were sevoflurane or desflurane. 
Maintenance of anesthesia and pharmacologic choice for controlled hypotension included 
sufentanil, propofol, esmolol, or nitroglycerine.  
Pediatric dosing of TXA for initial bolus and subsequent infusion varied among 
anesthesia providers. Initial TXA bolus ranged from 10-20 mg/kg. Subsequent infusion rates 
ranged from 5-10 mg/kg/hr. Adult dosing of TXA began with an initial bolus of 1g.   
Subsequent infusion rates varied widely based on surgeon preference, with some providers 
requesting no infusion after initial intraoperative bolus. Although variation in dosage of 
intraoperative TXA was noted, administered dose was consistent with research guidelines and  
recommendations noted in literature review.  
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Study Limitations 
    There were several study limitations that were identified throughout the research process. 
The retrospective study design limited results to association of variables instead of causation. 
Incomplete documentation excluded patients in this research, which contributed to the small 
sample size. However, sample size utilized in this study matched and, in some cases, exceeded 
sample sizes in literature reviewed cases. Additionally, TXA had only been used clinically in 
elective craniofacial surgeries at CAMC since 2015, owing to the limited sample size for the 
TXA group.  
This study design also did not allow for standardization of anesthetic techniques such as 
pharmacologic method of controlled hypotension. Estimation of blood loss is a subjective 
measurement among anesthesia providers, as variable amounts of irrigation were used, and lap 
pads, tapes, and sponges were not weighed for accurate fluid measurement. Finally, dosing of 
TXA and surgical provider was not standardized. 
IMPLICATIONS AND RECOMMENDATIONS 
 The results of this study did not support the hypotheses that intraoperative administration 
of TXA in patients who underwent elective craniofacial surgery would be associated with 
decreased estimated surgical blood loss and a decreased need for blood transfusion throughout 
the operative period versus patients who did not receive intraoperative TXA. Since intraoperative 
administration of TXA was not significantly associated with decrease in blood loss or need for 
intraoperative blood transfusion, the hypotheses were rejected. It would be beneficial to conduct 
a prospective study on this topic in order to reduce limitations present in this study. Anesthetic 
techniques and TXA dosage could be standardized among all patients as well as utilization of a 
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metric scale for more accurate blood loss estimation. Moreover, patients undergoing the same 
surgical procedure could be studied. 
CONCLUSION 
 The intraoperative administration of TXA was not associated with decreased estimated 
surgical blood loss or decreased need for intraoperative blood transfusion in patients who 
underwent elective craniofacial surgery. The results of this retrospective, cohort study concluded 
that increasing patient age was associated with both decreased likelihood for blood transfusion as 
well as decreased estimated blood loss.  
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APPENDICES 
 
Appendix A: ICD-10-PCS Codes 
 Procedures of the skull: 0NS004Z (Reposition skull with internal fixation device, open 
approach), 0NS005Z (Reposition skull with external fixation device, open approach), 0NS00ZZ 
(Reposition skull, open approach), 0NS0XZZ (Reposition skull, external approach), 0NB00ZZ 
(Excision of skull, open approach), 0NU107Z (Supplement frontal bone with autologous tissue 
substitute, open approach), 0NU10JZ (Supplement frontal bone with synthetic substitute, open 
approach), 0NU10KZ (Supplement frontal bone with nonautologous tissue substitute, open 
approach), 0NUM07Z (Supplement right zygomatic bone with autologous tissue substitute, open 
approach), 0NUM0JZ (Supplement right zygomatic bone with synthetic substitute, open 
approach), 0NUM0KZ (Supplement right zygomatic bone with nonautologous tissue substitute, 
open approach), 0NUN07Z (Supplement left zygomatic bone with autologous tissue substitute, 
open approach), 0NUN0JZ (Supplement left zygomatic bone with synthetic substitute, open 
approach), 0NUN0KZ (Supplement left zygomatic bone with nonautologous tissue substitute, 
open approach), 0WU207Z (Supplement face with autologous tissue substitute, open approach), 
0WU20JZ (Supplement face with synthetic substitute, open approach), 0WU20KZ (Supplement 
face with nonautologous tissue substitute, open approach), 0NQ0ZZ (Repair skull, open 
approach), 0N800ZZ (Division of skull, open approach). 
Procedures of the orbit: 0NUP07Z (Supplement right orbit with autologous tissue 
substitute, open approach), 0NUP0JZ (Supplement right orbit with synthetic substitute, open 
approach), 0NUP0KZ (Supplement right orbit with nonautologous tissue substitute, open 
approach), 0NSP0ZZ (Reposition right orbit, open approach), 0NSPXZZ (Reposition right orbit, 
external approach), 0NUQ07Z (Supplement left orbit with autologous tissue substitute, open 
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approach), 0NUQ0JZ (Supplement left orbit with synthetic substitute, open approach), 
0NUQ0KZ (Supplement left orbit with nonautologous tissue substitute, open approach), 
0NSQ0ZZ (Reposition left orbit, open approach), 0NSQXZZ (Reposition left orbit, external 
approach). 
Procedures of the maxilla: 0NSR04Z (Reposition maxilla with internal fixation device, 
open approach), 0NSR04Z (Reposition maxilla with external fixation device, open approach), 
0NSR0ZZ (Reposition maxilla, open approach), 0NSRXZZ (Reposition maxilla, external 
approach), 0NBR0ZZ (Excision of maxilla, open approach), 0NQR0ZZ (Repair of maxilla, open 
approach), 0NUR07Z (Supplement maxilla with autologous tissue substitute, open approach), 
0NUR0JZ (Supplement maxilla with synthetic substitute, open approach), 0NUR0KZ 
(Supplement maxilla with nonautologous tissue substitute, open approach). 
Procedures of the mandible: 0NST04Z (Reposition right mandible with internal fixation 
device, open approach), 0NST05Z (Reposition right mandible with external fixation device, open 
approach), 0NST0ZZ (Reposition right mandible, open approach), 0NSTXZZ (Reposition right 
mandible, external approach), 0NSV04Z (Reposition left mandible with internal fixation device, 
open approach), 0NSV05Z (Reposition left mandible with external fixation device, open 
approach), 0NSV0ZZ (Reposition left mandible, open approach), 0NSVXZZ (Reposition left 
mandible, external approach), 0NBT0ZZ (Excision of right mandible, open approach), 
0NBV0ZZ (Excision of left mandible, open approach), 0NQT0ZZ (Repair right mandible, open 
approach), 0NQV0ZZ (Repair left mandible, open approach). 
Procedures of the jaw: 0W0407Z (Alteration of upper jaw with autologous tissue 
substitute, open approach), 0W040JZ (Alteration of upper jaw with synthetic substitute, open 
approach), 0W040KZ (Alteration of upper jaw with nonautologous tissue substitute, open 
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approach), 0W040ZZ (Alteration of upper jaw, open approach), 0WU407Z (Supplement upper 
jaw with autologous tissue substitute, open approach), 0WU40JZ (Supplement upper jaw with 
synthetic substitute, open approach), 0WU40KZ (Supplement upper jaw with nonautologous 
tissue substitute, open approach), 0WU507Z (Supplement lower jaw with autologous tissue 
substitute, open approach), 0WU50JZ (Supplement lower jaw with synthetic substitute, open 
approach), 0WU50KZ (Supplement lower jaw with nonautologous tissue substitute, open 
approach). 
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Appendix B:  Data Collection Tool 1 
 
Patient Study Number CAMC Patient Identification Number 
1  
2  
3  
4  
5  
…  
200  
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Appendix C:  Data Collection Tool 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Study 
Number 
Age  
(year) 
Gender 
(M/F) 
BMI  
(kg/m2) 
Weight 
(kg) 
ASA  
Physical 
Status 
Class 
(I-IV) 
TXA 
Administration 
(N=0 
Y=1) 
Estimated 
Specific 
Blood 
Volume 
(mL/kg) 
Estimated 
Blood 
Volume 
(EBV) 
(mL) 
Estimated 
Blood 
Loss (ml) 
Estimated 
Blood 
Loss (% 
of EBV) 
Intraoperative 
Blood 
Transfusion 
(Y/N) 
1            
2            
3            
4            
5            
…            
200            
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Appendix D: IRB Protocol Approval 
 
